Investigating how FBXL16 contributes to breast cancer treatment resistance and spread
Official title: FBXL16 as a novel factor in promoting endocrine therapy resistance and metastasis of ER+ breast cancer
Funded at Wright State University · NIH-10794658 · Data updated 2026-11-12
This study is looking at how a protein called FBXL16 influences estrogen receptor-positive breast cancer, especially why some patients don’t respond to hormone therapy and how the cancer might spread, with the goal of finding better treatment options for those facing advanced breast cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $450,000 |
| NIH project number | 1R15CA280818-01A1 |
| Project ID | NIH-10794658 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced estrogen receptor-positive breast cancer who are experiencing resistance to current endocrine therapies.
✕Less likely to help
Patients with early-stage breast cancer or those who do not have estrogen receptor-positive tumors may not benefit from this research.
What this research studies
This research focuses on understanding how the protein FBXL16 affects the behavior of estrogen receptor-positive (ER+) breast cancer, particularly in relation to resistance to endocrine therapy and the cancer's ability to spread. By examining the role of FBXL16 in stabilizing the estrogen receptor and its co-activators, the study aims to uncover new mechanisms that lead to treatment failure in patients. The researchers will conduct experiments to analyze the effects of FBXL16 on cancer cell behavior and response to therapy, which could provide insights into improving treatment strategies for patients with advanced breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets that improve treatment outcomes for patients with ER+ breast cancer.
How similar studies have gone: While the specific role of FBXL16 in breast cancer is being explored, similar studies have shown that targeting protein interactions can lead to breakthroughs in understanding treatment resistance.
Where this research is happening
-
Wright State University
Dayton, United States Active
Researchers
- Principal investigator: Long, Weiwen — Wright State University
- Study coordinator: Long, Weiwen
Related research
Other NIH-funded projects on the same topics.
-
ER+ Breast Cancer Bone Metastasis in a Real Body Environment
This grant aims to understand why estrogen receptor alpha–positive breast cancer often spreads to bone and how the bone environment and immune system affect treatment resistance.
-
Heavy Metals and Breast Cancer Treatment Resistance
This project explores how exposure to heavy metals might make ER+ breast cancer harder to treat and how we might overcome this challenge.
-
How heavy metals affect breast cancer treatment and progression
This study is looking at how being exposed to heavy metals like arsenic and lead might make certain types of breast cancer more aggressive and harder to treat, with the goal of finding new ways to help patients with hormone receptor-positive breast cancer.
-
Prolactin signaling and brain metastasis in HER2-positive breast cancer
Researchers are studying how prolactin signals help HER2-positive breast cancer cells grow in the brain, with the goal of finding new ideas to prevent brain metastases.
-
Stable, ultra-tight peptides to block EphB4 and stop TNBC spread
A new peptide-based approach aims to block a cancer molecule called EphB4 to prevent metastasis in triple-negative breast cancer, especially in African American women.
-
How an immune signal in brain support cells helps breast cancer spread to the brain
This project looks at whether a specific immune signal in brain support cells (astrocytes) helps breast cancer cells grow in the brain, aiming to help people with breast cancer that has spread to the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.